Status: Not yet recruiting
Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC
A Phase II, interventional study of neoadjuvant durvalumab (MEDI 4736) and platinum-based Chemotherapy, followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab, in participants with borderline resectable stage III Non-small Cell Lung Cancer (NSCLC) (ACCESS)
Participants needed: 80
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Bi NanUpdated: May 31, 2025Locations: 1
Eligibility criteria
1. Participant must be ≥ 18 years, at the time of screening. 2. Histologically o... [+22]
Existence of more than one primary tumor, such as: mixed small cell and NSCLC hi... [+24]